...
首页> 外文期刊>Clinical transplantation. >No detrimental effect on renal function during long-term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study.
【24h】

No detrimental effect on renal function during long-term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study.

机译:在肾脏移植的莱斯科尔评估(ALERT)研究中,长期使用氟伐他汀对肾移植受者的肾功能无有害影响。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Concerns have recently been raised regarding a potential harmful effect of statins on renal function. This study investigated the effect of fluvastatin treatment on renal function in renal transplant recipients enrolled in the Assessment of Lescol in Renal Transplantation (ALERT) trial. METHODS: ALERT was a randomized, double-blind, placebo-controlled study of the effect of fluvastatin, 40-80 mg daily (n = 1050) or placebo (n = 1052) on cardiac and renal outcomes in renal transplant recipients over a follow-up period of five to six years. The incidence of graft loss, changes in serum creatinine, calculated creatinine clearance and proteinuria, and the incidence of renal adverse events (AEs) were assessed in both treatment groups. RESULTS: Fluvastatin treatment in ALERT had no significant effect compared with placebo on renal function, assessed by serum creatinine (overall adjusted mean +/- SEM: fluvastatin, 175.4 +/- 2.20 micromol/L; placebo, 172.7 +/- 2.20 micromol/L; p = 0.39), creatinineclearance (fluvastatin, 55.3 +/- 0.30 mL/min; placebo, 55.8 +/- 0.30 mL/min; p = 0.26) or proteinuria (fluvastatin, 0.58 +/- 0.03 g/24 h; placebo, 0.53 +/- 0.03 g/24 h; p = 0.31). There were no significant differences between treatment groups when the 283 patients suffering graft loss were excluded from the analysis. Fluvastatin also had no detrimental effect on creatinine clearance or proteinuria in the subgroup of 340 diabetic patients without graft loss in ALERT. No notable differences in the rate of renal or musculoskeletal AEs were observed between fluvastatin and placebo groups. CONCLUSIONS: Fluvastatin had no detrimental effect on renal function, or the risk of renal AEs, in renal transplant recipients with or without diabetes enrolled in ALERT. Fluvastatin treatment for the prevention of cardiac events may therefore be used without fear of jeopardizing renal function.
机译:背景:最近人们开始关注他汀类药物对肾功能的潜在有害作用。这项研究调查了氟伐他汀治疗对参加肾脏移植莱斯科尔评估(ALERT)试验的肾移植受者肾功能的影响。方法:ALERT是一项随机,双盲,安慰剂对照研究,在随访期间,每天40-80 mg氟伐他汀(n = 1050)或安慰剂(n = 1052)对肾移植受者心脏和肾脏结局的影响长达五到六年的时间。在两个治疗组中评估了移植物丢失的发生率,血清肌酐的变化,肌酐清除率和蛋白尿的计算值以及肾脏不良事件(AE)的发生率。结果:通过血清肌酐评估,ALERT中的氟伐他汀治疗与安慰剂相比对肾功能没有显着影响(总体调整后平均+/- SEM:氟伐他汀为175.4 +/- 2.20 micromol / L;安慰剂为172.7 +/- 2.20 micromol / L L; p = 0.39),肌酐清除率(氟伐他汀,55.3 +/- 0.30mL / min;安慰剂,55.8 +/- 0.30mL / min; p = 0.26)或蛋白尿(氟伐他汀,0.58 +/- 0.03g / 24h;尿液;安慰剂,0.53 +/- 0.03 g / 24 h; p = 0.31)。当分析中排除了283名遭受移植物丢失的患者时,治疗组之间无显着差异。氟伐他汀对340例糖尿病患者亚组中肌酐清除率或蛋白尿也无不利影响,而ALERT患者无移植物丢失。在氟伐他汀和安慰剂组之间,未观察到肾脏或肌肉骨骼AE的发生率有显着差异。结论:氟维他汀对有或没有糖尿病的肾移植受者,均未对肾功能或肾脏发生AE的危险性产生不良影响。因此,可以使用氟伐他汀治疗来预防心脏事件,而不必担心会损害肾功能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号